Screener
Monte Rosa Therapeutics, Inc. GLUE Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s total equity?
- Monte Rosa Therapeutics, Inc. (GLUE) reported total equity of $487.28M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s total equity changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s total equity increased by 81.8% year-over-year, from $268.08M to $487.28M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s total equity has grown at a 36.8% compound annual growth rate (CAGR), from -$48.73M to $233.06M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Monte Rosa Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude